, Volume 10, Issue 1, pp 22–32 | Cite as

La prévention des cancers du sein (Étude Star)



Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hill C, Doyan F (2005) La fréquence des cancers en France en 2000 et son évolution depuis 1950. Bull cancer 1: 7–11Google Scholar
  2. 2.
    Ferlay J, Autier P, Boniol M, et al. (2007) Estimates of cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581–592PubMedCrossRefGoogle Scholar
  3. 3.
    Phillips KA, Glendon G, Knight JA (1999) Putting the risk of breast cancer in perspective. N Engl J Med 340: 141–144PubMedCrossRefGoogle Scholar
  4. 4.
    Feuer EJ, Wun LM, Boring CC, et al. (1993) The lifetime of developing breast cancer. J Natl Cancer Inst 85: 892–897PubMedCrossRefGoogle Scholar
  5. 5.
    Tchou J, Morrow M (2003) Overview of clinical risk assessment. In: « Managing Breast Cancer Risk. Monica Morrow & V. Craig Jordan. BC Decker Inc. Hamilton LondonGoogle Scholar
  6. 6.
    Kelsey JL (1979) A review of the epidemiology of human breast cancer. Epidemiol Rev 1: 74–109PubMedGoogle Scholar
  7. 7.
    Dupont WD, Parl FF, Hartmann WH, et al. (1993) Breast cancer risk associated with proliferative disease and atypical hyperplasma. Cancer 71: 1258–1265PubMedCrossRefGoogle Scholar
  8. 8.
    Gail MH, Brinto LA, Byar DP, et al. (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81: 1979–1986CrossRefGoogle Scholar
  9. 9.
    Claus EB, Risch N, Thompson WD (1994) Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 73: 643–651PubMedCrossRefGoogle Scholar
  10. 10.
    Layde PM, Webster LA, Baughman, AL, et al. (1989) The independent association of parity age at first full term pregnancy, and duration of breastfeeding with the risk of breast cancer. J Clin Epidemiol 42: 963–973PubMedCrossRefGoogle Scholar
  11. 11.
    Warner E, Plewes DB, Shumak RS, et al. (2001) Comparison of breast magnetic resonance imaging, mammography and ultrasound for surveillance of women with a hereditary breast cancer. J Clin Oncol 19: 3524–3531PubMedGoogle Scholar
  12. 12.
    Kinne D (1991) Management of the controlateral breast. In: Breast Diseases Ed.: JR Harris, S Hellman, IC Henderson, DW Kinné. JB Lippincott company Philadelphia, New York, London, Hagerstown 827–834Google Scholar
  13. 13.
    Early Breast Cancer Tralists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1451–1467Google Scholar
  14. 14.
    The ATAC Trialits’ Group (2002) Arimidex, tamoxifen alone or in combination: first results of the ATAC randomized trial. Lancet 359: 2131–2139CrossRefGoogle Scholar
  15. 15.
    The BIG 1–98 Collaborative trial (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353: 2747–2757CrossRefGoogle Scholar
  16. 16.
    Veronesi U, De Palo G, Marubini E, et al. (1999) Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 91: 1847–1856PubMedCrossRefGoogle Scholar
  17. 17.
    Lacassagne A (1936) Hormonal pathogenesis of adenocarcinoma of the breast. Am J Cancer 27: 217–225Google Scholar
  18. 18.
    Beatson GW (1986) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2: 102–105, 104–7Google Scholar
  19. 19.
    Early Breast Cancer Trialists’ Collaborative Group (1996) Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 348: 1189–1196CrossRefGoogle Scholar
  20. 20.
    Collaborative Group on hormonal factors in breast cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350: 1047–1057CrossRefGoogle Scholar
  21. 21.
    Obwegeser R, Auerbach L, Kubista E (1997) Gynaecological aspects of tamoxifen treatment in breast cancer patients. Cancer Treat Rev 23: 289–304PubMedCrossRefGoogle Scholar
  22. 22.
    Love RR, Mazess RB, Barden PD, et al. (1992) Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326: 852–856PubMedCrossRefGoogle Scholar
  23. 23.
    Saphner T, Tormey DL, Gray R (1991) Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 9: 286–294PubMedGoogle Scholar
  24. 24.
    Love RR, Newcomb PA, Wiebe DA, et al. (1990) Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node negative breast cancer. J Natl Cancer Inst 82: 1327–1332PubMedCrossRefGoogle Scholar
  25. 25.
    McDonald CC, Stewart HJ (1991) Fatal myocardial infarctions in the Scottish adjuvant tamoxifen trial. Br Med J 303: 435–437CrossRefGoogle Scholar
  26. 26.
    Delmas PD, Bjarnasson NH, Mitlak BH, et al. (1997) Effect of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 337: 1641–1647PubMedCrossRefGoogle Scholar
  27. 27.
    Fisher B, Costantino JP, Wickerham DL, et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Nat Cancer Inst 90: 1371–1388PubMedCrossRefGoogle Scholar
  28. 28.
    Powles T, Eeles R, Ashley S, Easton D, et al. (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352: 98–101PubMedGoogle Scholar
  29. 29.
    Veronesi U, Maisonneuve P, Costa A, et al. (1998) Prevention of breast cancer with tamoxifen: preliminary findings from Italian randomised trial among hysterectomised women. Lancet 352: 93–97PubMedGoogle Scholar
  30. 30.
    Cummings SR, Eckert S, Krueger KA, et al. (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. JAMA 281: 2189–2197PubMedCrossRefGoogle Scholar
  31. 31.
    Vogel VG, Costantino JP, Wickerham DL, et al. (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 295: 2727–2741PubMedCrossRefGoogle Scholar
  32. 32.
    Land SR, Wickerham DL, Costantino JP, et al. (2006) Patient reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 295: 2742–2751PubMedCrossRefGoogle Scholar
  33. 33.
    Mc Donnell SK, Schaid DJ, Myers JL, et al. (2001) Efficacy of controlateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 19: 3938–3943Google Scholar
  34. 34.
    Hartmann LC, Schaid DJ, Woods JE, et al. (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340: 77–84PubMedCrossRefGoogle Scholar
  35. 35.
    American Society of Plastic and Reconstructive Surgeons (1994) Position paper: Prophylactic mastectomy. Arlington Heights, ILGoogle Scholar

Copyright information

© Springer Verlag France 2008

Authors and Affiliations

  1. 1.Centre Azureen de cancérologieMouginsFrance

Personalised recommendations